980
Participants
Start Date
November 19, 2024
Primary Completion Date
April 1, 2026
Study Completion Date
April 1, 2026
IIV-HD
Inactivated, split-virion
rC19 (dose 1)
Protein subunit
IIV-HD + rC19 (dose 1)
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 2)
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 3)
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
IIV-HD + rC19 (dose 4)
IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
Placebo (0.9% NaCl)
Normal saline
Synexus New York Site Number : 8400007, New York
Synexus Clinical Research US - Atlanta- Site Number : 8400001, Atlanta
Synexus Clinical Research US, Inc. - The Villages Site Number : 8400011, The Villages
Simon Williamson Clinic - Birmingham- Site Number : 8400003, Birmingham
Synexus Clinical Research- Site Number : 8400004, Chicago
Synexus Clinical Research - St. Louis- Site Number : 8400010, Creve Coeur
Synexus Clinical Research US - Dallas- Site Number : 8400005, Dallas
Synexus Clinical Research US - San Antonio- Site Number : 8400009, San Antonio
Optimal Research, LLC Site Number : 8400002, Austin
Synexus Salt Lake City Site Number : 8400008, Salt Lake City
Orange Grove Family Practice- Site Number : 8400012, Tucson
AES - DRS - Optimal Research Alabama - Huntsville Site Number : 8400006, Huntsville
Lead Sponsor
Sanofi
INDUSTRY